Brickell’s Phase III Data Sets Up NDA Filing In Axillary Hyperhidrosis

 
• By Joseph Haas

Meeting all primary and secondary endpoints in a pair of pivotal trials, Brickell says sofpironium bromide gel will be ready for FDA filing in mid-2022. The topical is already approved in Japan as Ecclock.

Diagnosis - Hyperhidrosis. Medical Concept with Blurred Text, Stethoscope, Pills and Syringe on Green Background. Selective Focus. 3D Render.
Brickell hopes to improve the standard of care for axillary hyperhidrosis

More from Clinical Trials

More from R&D